FDA approves Hemgenix (etranacogene dezaparvovec) to treat hemophilia B | Carrick Pharmacy
(Carrick Pharmacy News) There’s a new treatment for a serious bleeding disorder. The US Food and Drug Administration (FDA) recently approved Hemgenix (etranacogene dezaparvovec) to treat hemophilia B. This treatment is a gene therapy meant for “adults with Hemophilia B (congenital Factor IX deficiency) who currently use Factor IX prophylaxis therapy, or have current or historical …
